文献速递膀胱癌与上尿路尿路上皮癌

替雷利珠单抗用于顺铂不耐受高危上尿路尿路上皮癌新辅助治疗的2期研究

A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2025-02-25

这项单臂2期试验纳入20例顺铂不耐受的高危上尿路尿路上皮癌患者,术前接受替雷利珠单抗新辅助治疗。病理完全缓解率为20%,45%的患者重新分期至≤pT1,3/4级治疗相关不良事件发生率为15%。中位无病生存期和总生存期均未达到。

要点

  • 20例顺铂不耐受高危上尿路尿路上皮癌患者接受替雷利珠单抗新辅助治疗,病理完全缓解率为20%。
  • 45%的患者重新分期至≤pT1,3/4级治疗相关不良事件发生率为15%。
  • MRI表观扩散系数熵升高及肿瘤间质PD-L1+CD68+巨噬细胞增多可能预测新辅助替雷利珠单抗的疗效。

核心结论

  • 新辅助替雷利珠单抗在顺铂不耐受的高危上尿路尿路上皮癌患者中显示出有前景的疗效和可控的毒性。
  • MRI表观扩散系数熵升高和肿瘤间质PD-L1+CD68+巨噬细胞的存在可能作为新辅助替雷利珠单抗疗效的潜在预测因素。

研究设计与样本

  • 单臂2期试验(NCT04672330),纳入20例高危上尿路尿路上皮癌患者。
  • 高危上尿路尿路上皮癌定义为内镜活检或尿细胞学证实的高级别上尿路尿路上皮癌、影像学证据显示浸润(cT2-T4N0-2M0)和/或肾积水。
  • 入组标准包括东部肿瘤协作组体能状态评分为0至2、既往未接受过全身治疗以及顺铂不耐受。
  • 患者在根治性手术前接受新辅助替雷利珠单抗治疗,并在第三剂前和手术前分别进行增强MRI检查。

主要发现

  • 20例患者中,13例接受根治性肾输尿管切除术,1例接受内镜消融,3例接受输尿管节段性切除术;3例因疾病进展或不良事件拒绝手术。
  • 病理完全缓解率为20%,45%的患者重新分期至≤pT1。
  • 中位无病生存期和总生存期均未达到。
  • 3/4级治疗相关不良事件发生率为15%。
  • MRI分析显示,部分缓解患者的表观扩散系数熵较高;探索性分析显示,部分缓解和完全缓解患者的肿瘤间质中PD-L1+CD68+巨噬细胞和PD-1+CD8+ T细胞增多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the efficacy and safety of tislelizumab as neoadjuvant therapy in patients with cisplatin-ineligible high-risk upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: In this single-arm phase 2 trial (NCT04672330), 20 patients with high-risk UTUC were enrolled. Eligibility criteria included high-risk UTUC (defined as high-grade UTUC confirmed by endoscopic biopsy or urinary cytology, radiographic evidence of invasion [cT2-T4N0-2M0], and/or hydronephrosis), an Eastern Cooperative Oncology Group performance status of 0 to 2, no previous systemic therapy, and cisplatin ineligibility. Patients received neoadjuvant tislelizumab before radical surgery. Contrast-enhanced MRI was performed before the third dose and again before surgery. The primary end point was pathological complete response rate (ypT0N0). Secondary end points included pathological response rate (≤ypT1N0), objective response rate, disease-free survival, safety profile, and perioperative complications. Multiplex immunofluorescence assessed immune cell populations in the tumor microenvironment. RESULTS: Among the 20 patients, 13 underwent radical nephroureterectomy, 1 received endoscopic ablation, and 3 had segmental ureteral resection. Three patients declined surgery because of disease progression or adverse events. The pathological complete response rate was 20%, with 45% of patients restaged to ≤ pT1. Median disease-free survival and overall survival were not reached. Grade 3/4 treatment-related adverse event occurred in 15% of patients. MRI analysis revealed higher apparent diffusion coefficient entropy in patients with partial response. Exploratory analysis showed increased PD-L1+CD68+ macrophages and PD-1+CD8+ T cells in the tumor stroma of partial and complete responders. CONCLUSIONS: Neoadjuvant tislelizumab showed promising efficacy and manageable toxicity in patients with high-risk, cisplatin-ineligible UTUC. Increased apparent diffusion coefficient entropy on MRI and the presence of PD-L1+CD68+ macrophages in the tumor stroma may serve as potential predictors of response to neoadjuvant tislelizumab.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Huang J, Cai X, Ng C, et al. A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma. J Urol. 2025. PMID: 39999445. doi:10.1097/JU.0000000000004475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。